Daxor awarded support from NIH catalyze preclinical services program

Daxo announces it has been accepted into the National Institutes of Health, NIH, Catalyze Preclinical Services Program. This program supports preclinical development, including studies and activities needed to meet the regulatory requirements for therapeutic and device submissions of technologies relevant to the National Heart, Lung, and Blood Institute’s mission. This effort will be done in collaboration with two nationally recognized contract research organizations, to support the continued development of Daxor’s non-nuclear fluorescent blood volume analyzer device. “This exciting initiative will facilitate a tracer with practical applications in settings as diverse as a doctor’s office to critical care units or even intraoperatively as well. We are gratified to receive the valuable support of the NIH’s Catalyze Program which recognizes the significant impact that this technology will bring once commercialized. The capacity to improve outcomes for millions of patients at multiple points within the healthcare system is exactly the innovative work that fits within the scope of the Catalyze Program and Daxor’s vision – optimal blood for all,” said Michael Feldschuh, Daxor’s CEO and President. The Catalyze Program is an ultra-selective initiative to fund the most promising future medical innovations by the NIH. The Catalyze Program is designed to fund key preclinical research of technologies and transformative platforms by NHLBI. Daxor will receive support and direct funding from third-party labs to conduct needed preclinical work toward an FDA submission of its next generation non-nuclear tracer system. This initiative is separate from the existing initiative to launch a next generation bedside analyzer that is undergoing validation in preparation for an FDA submission slated for before the end of 2023